chronic lymphocytic leukemia news from FierceBiotech

Looking to boost its pipeline, the U.K.'s Antisoma is paying $52 million for Boston oncology company Xanthus Pharmaceutical. Antisoma gains three drug candidates:Xanafide, which is in Phase III trial... Read more...

After seeing its stock price shed about a third of its value since last summer, Cephalon is keeping its fingers crossed that tomorrow's scheduled regulatory decision on its cancer drug Treanda can... Read more...

Genta is going to have to wait a little longer before it gets final word on its appeal of the FDA's rejection... Read more...

Denmark's Santaris Pharma has banked $30 million from its latest venture round. Gilde Healthcare Partners put up much of that money with BankInvest, Novo, LD, Forbion Capital Partners, Global Life... Read more...

> The international relief agency Oxfam lays the decline in pharma's overall stock performance at the... Read more...

Cephalon is touting Phase III results of its non-Hodgkin's lymphoma drug Treanda. In the trial, 100 patients who were not responding to Genentech and Biogen Idec's Rituxan were given Treanda. The... Read more...

AstraZeneca, BMS ink diabetes drug pact

... Read more...

Press Release: Genentech and Seattle Genetics Announce Exclusive Global Licensing Agreement for SGN-40

... Read more...

Shares of Seattle Genetics shot up 31.5 percent this morning after it announced that it would gain $60 million up front and more than $800 million in potential milestones from Genentech from its newly signed development pact for SGN-40. Genentech is committed to pay $20 million of those milestones payments in the first two years of the agreement as Seattle Genetics is reimbursed for clinical trials. The therapy is an early-stage cancer treatment being studied for multiple myeloma, chronic …

... Read more...

GlaxoSmithKline (GSK) and Genmab A/S today announced a worldwide agreement to co-develop and commercialize HuMax- CD20(TM) (ofatumumab), a fully human monoclonal antibody in late stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma (NHL) and in Phase II for rheumatoid arthritis (RA).

... Read more...